Cyclic Nucleotide Phosphodiesterases, Type 5
"Cyclic Nucleotide Phosphodiesterases, Type 5" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclic nucleotide phosphodiesterase subfamily that is highly specific for CYCLIC GMP. It is found predominantly in vascular tissue and plays an important role in regulating VASCULAR SMOOTH MUSCLE contraction.
Descriptor ID |
D054706
|
MeSH Number(s) |
D08.811.277.352.640.150.500 D08.811.277.352.640.155.500 D12.644.360.008.500 D12.644.360.009.500 D12.776.476.008.500 D12.776.476.009.500
|
Concept/Terms |
Cyclic Nucleotide Phosphodiesterases, Type 5- Cyclic Nucleotide Phosphodiesterases, Type 5
- Phosphodiesterase 5A, cGMP-Specific
- Phosphodiesterase 5A, cGMP Specific
- cGMP-Specific Phosphodiesterase 5A
- Phosphodiesterase 5A
- Phosphodiesterase Type 5
- Type 5, Phosphodiesterase
- Phosphodiesterase 5
- Phosphodiesterase-5
- Phosphodiesterase V
- cGMP-Binding, cGMP-Specific 3',5'-cyclic Nucleotide Phosphodiesterase
- PDE5 Phosphodiesterases
- Phosphodiesterases, PDE5
- Phosphodiesterase Type V
- Type V, Phosphodiesterase
|
Below are MeSH descriptors whose meaning is more general than "Cyclic Nucleotide Phosphodiesterases, Type 5".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Hydrolases [D08.811.277]
- Esterases [D08.811.277.352]
- Phosphoric Diester Hydrolases [D08.811.277.352.640]
- 3',5'-Cyclic-AMP Phosphodiesterases [D08.811.277.352.640.150]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D08.811.277.352.640.150.500]
- 3',5'-Cyclic-GMP Phosphodiesterases [D08.811.277.352.640.155]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D08.811.277.352.640.155.500]
- Amino Acids, Peptides, and Proteins [D12]
- Peptides [D12.644]
- Intracellular Signaling Peptides and Proteins [D12.644.360]
- 3',5'-Cyclic-AMP Phosphodiesterases [D12.644.360.008]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D12.644.360.008.500]
- 3',5'-Cyclic-GMP Phosphodiesterases [D12.644.360.009]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D12.644.360.009.500]
- Proteins [D12.776]
- Intracellular Signaling Peptides and Proteins [D12.776.476]
- 3',5'-Cyclic-AMP Phosphodiesterases [D12.776.476.008]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D12.776.476.008.500]
- 3',5'-Cyclic-GMP Phosphodiesterases [D12.776.476.009]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D12.776.476.009.500]
Below are MeSH descriptors whose meaning is more specific than "Cyclic Nucleotide Phosphodiesterases, Type 5".
This graph shows the total number of publications written about "Cyclic Nucleotide Phosphodiesterases, Type 5" by people in this website by year, and whether "Cyclic Nucleotide Phosphodiesterases, Type 5" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2006 | 0 | 1 | 1 |
2019 | 0 | 2 | 2 |
2020 | 0 | 1 | 1 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclic Nucleotide Phosphodiesterases, Type 5" by people in Profiles.
-
Grandin EW, Gulati G, Nunez JI, Kennedy K, Rame JE, Atluri P, Pagani FD, Kirklin JK, Kormos RL, Teuteberg J, Kiernan MS. Outcomes With Phosphodiesterase-5 Inhibitor Use After Left Ventricular Assist Device: An STS-INTERMACS Analysis. Circ Heart Fail. 2022 04; 15(4):e008613.
-
Gulati G, Kiernan MS. Phosphodiesterase-5 Inhibitor Therapy for Left Ventricular Assist Device Patients: More Data, More Questions. J Am Heart Assoc. 2020 07 21; 9(14):e017585.
-
Tyagi R, Elfawal MA, Wildman SA, Helander J, Bulman CA, Sakanari J, Rosa BA, Brindley PJ, Janetka JW, Aroian RV, Mitreva M. Identification of small molecule enzyme inhibitors as broad-spectrum anthelmintics. Sci Rep. 2019 06 24; 9(1):9085.
-
Hindle AG, Allen KN, Batten AJ, H?ckst?dt LA, Turner-Maier J, Schulberg SA, Johnson J, Karlsson E, Lindblad-Toh K, Costa DP, Bloch DB, Zapol WM, Buys ES. Low guanylyl cyclase activity in Weddell seals: implications for peripheral vasoconstriction and perfusion of the brain during diving. Am J Physiol Regul Integr Comp Physiol. 2019 06 01; 316(6):R704-R715.
-
Zhang L, Zhang Z, Zhang RL, Cui Y, LaPointe MC, Silver B, Chopp M. Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke. Brain Res. 2006 Nov 06; 1118(1):192-8.